Work

Clinical utility of circulating tumor DNA sequencing with a large panel in patients with advanced soft‐tissue sarcomas

Year: 2023

Type: article

Abstract: Clinical utility of circulating tumor DNA sequencing with a large panel in patients with advanced soft-tissue sarcomasTo the editor Soft-tissue sarcomas (STS) represent a very heterogeneous group of rare tumors including more than 100 different subtypes [1].Surgery and neo/adjuvant radiation therapy represent the cornerstone of treatment for STS.However, despite an optimal resection of the tumor, up to 40% of patients will develop metastatic relapse and will die from the disease [1].Doxorubicin represents the first-line standard of care for patients with advanced disease since the 1970s, despite several attempts to identify better regimens.The median overall survival (OS) of patients with metastatic disease is < 18 months and has only modestly improved over the past 20 years [2].We and others have previously reported that nextgeneration sequencing (NGS) of tumor tissues allows the identification of genomic aberrations with the potential to influence and personalize therapy in up to 50% of patients with advanced STS [3,4].Genomic profiling of circulating tumor DNA (ctDNA) is increasingly used to tailor therapy in cancer patients.Indeed, such liquid biopsy has several advantages: noninvasiveness, reduced turnaround times for faster results, and the ability to fully capture the landscape of tumor heterogeneity [5].The aims of the present study were to investigate the impact of ctDNA profiling in a large cohort of patients with advanced STS included in two prospective precision medicine studies and to decipher the ctDNA molecular landscape of sarcoma.Between December 2020 and August 2021, 98 patients with advanced STS were included in two ongoing institutional molecular profiling studies (Bergonie Institute Profiling, BIP: NCT02534649; Gustave Roussy Profiling, STING: NCT04932525).Their character-

Source: 癌症：英文版

DOI: 10.1002/cac2.12461